| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 35 | 2023 | 1097 | 5.920 |
Why?
|
| Head and Neck Neoplasms | 39 | 2024 | 1060 | 5.400 |
Why?
|
| Oropharyngeal Neoplasms | 16 | 2024 | 132 | 4.030 |
Why?
|
| Mouth Neoplasms | 12 | 2023 | 198 | 3.350 |
Why?
|
| Papillomavirus Infections | 17 | 2024 | 263 | 3.200 |
Why?
|
| DNA, Neoplasm | 10 | 2020 | 266 | 2.280 |
Why?
|
| Thyroid Neoplasms | 12 | 2024 | 425 | 2.260 |
Why?
|
| Mutation | 28 | 2024 | 4159 | 1.450 |
Why?
|
| Carcinoma | 8 | 2022 | 438 | 1.320 |
Why?
|
| Receptor, Notch1 | 9 | 2020 | 94 | 1.240 |
Why?
|
| Papillomaviridae | 9 | 2022 | 155 | 1.220 |
Why?
|
| Tongue Neoplasms | 7 | 2023 | 52 | 1.210 |
Why?
|
| Carcinoma, Adenoid Cystic | 4 | 2025 | 43 | 1.110 |
Why?
|
| Laryngectomy | 8 | 2017 | 26 | 1.090 |
Why?
|
| Biomarkers, Tumor | 12 | 2022 | 1540 | 1.080 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2025 | 80 | 1.070 |
Why?
|
| Neck Dissection | 5 | 2017 | 67 | 1.050 |
Why?
|
| Exome | 5 | 2017 | 131 | 0.980 |
Why?
|
| Humans | 126 | 2025 | 89567 | 0.940 |
Why?
|
| Tonsillar Neoplasms | 3 | 2019 | 6 | 0.900 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2020 | 412 | 0.900 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 260 | 0.880 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 319 | 0.860 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 305 | 0.850 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 58 | 0.840 |
Why?
|
| Laryngeal Neoplasms | 5 | 2017 | 89 | 0.830 |
Why?
|
| Alphapapillomavirus | 4 | 2021 | 45 | 0.820 |
Why?
|
| Saliva | 3 | 2021 | 124 | 0.820 |
Why?
|
| Middle Aged | 56 | 2024 | 25996 | 0.760 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2024 | 1353 | 0.740 |
Why?
|
| Betacoronavirus | 3 | 2020 | 262 | 0.740 |
Why?
|
| Male | 69 | 2024 | 42464 | 0.730 |
Why?
|
| Pandemics | 4 | 2020 | 775 | 0.710 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 156 | 0.710 |
Why?
|
| Tracheotomy | 1 | 2020 | 18 | 0.700 |
Why?
|
| Neoplasm Staging | 14 | 2022 | 2003 | 0.690 |
Why?
|
| Palatine Tonsil | 1 | 2019 | 30 | 0.670 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 571 | 0.660 |
Why?
|
| Female | 69 | 2025 | 46371 | 0.660 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 165 | 0.650 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2016 | 47 | 0.630 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.610 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 161 | 0.610 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.610 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.610 |
Why?
|
| Thyroidectomy | 7 | 2022 | 171 | 0.580 |
Why?
|
| Prognosis | 17 | 2022 | 3783 | 0.580 |
Why?
|
| Life Style | 1 | 2018 | 174 | 0.560 |
Why?
|
| Liquid Biopsy | 4 | 2023 | 36 | 0.550 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 538 | 0.530 |
Why?
|
| NFI Transcription Factors | 1 | 2016 | 7 | 0.530 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 133 | 0.530 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 265 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1050 | 0.510 |
Why?
|
| Incidence | 8 | 2023 | 1598 | 0.510 |
Why?
|
| Disability Evaluation | 1 | 2016 | 139 | 0.510 |
Why?
|
| Aged | 36 | 2024 | 19144 | 0.500 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2014 | 153 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 2354 | 0.500 |
Why?
|
| Adult | 41 | 2024 | 26684 | 0.490 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 337 | 0.490 |
Why?
|
| Neck | 4 | 2015 | 104 | 0.480 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 1185 | 0.460 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 398 | 0.440 |
Why?
|
| Postoperative Complications | 8 | 2016 | 2296 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 152 | 0.430 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2024 | 15 | 0.430 |
Why?
|
| Salvage Therapy | 3 | 2015 | 231 | 0.430 |
Why?
|
| Carcinoma, Medullary | 1 | 2012 | 9 | 0.430 |
Why?
|
| Retrospective Studies | 20 | 2022 | 9112 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2012 | 23 | 0.430 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2023 | 70 | 0.400 |
Why?
|
| Lymph Nodes | 5 | 2017 | 552 | 0.400 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 94 | 0.390 |
Why?
|
| F-Box Proteins | 1 | 2011 | 11 | 0.390 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 20 | 0.390 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2011 | 172 | 0.380 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2023 | 83 | 0.380 |
Why?
|
| Clostridium | 4 | 2005 | 23 | 0.380 |
Why?
|
| Monitoring, Intraoperative | 4 | 2018 | 109 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2023 | 2878 | 0.370 |
Why?
|
| United States | 12 | 2023 | 7041 | 0.360 |
Why?
|
| Tonsillectomy | 3 | 2023 | 30 | 0.350 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 2 | 2022 | 17 | 0.350 |
Why?
|
| Esophageal Neoplasms | 2 | 2012 | 333 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 2502 | 0.340 |
Why?
|
| Aged, 80 and over | 18 | 2023 | 6766 | 0.330 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 175 | 0.330 |
Why?
|
| ras Proteins | 2 | 2020 | 130 | 0.330 |
Why?
|
| Receptors, Notch | 4 | 2022 | 126 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 488 | 0.310 |
Why?
|
| SEER Program | 3 | 2023 | 199 | 0.310 |
Why?
|
| Sex Factors | 5 | 2018 | 1073 | 0.300 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 52 | 0.300 |
Why?
|
| Parathyroid Hormone | 3 | 2018 | 220 | 0.300 |
Why?
|
| Age Factors | 5 | 2018 | 1877 | 0.290 |
Why?
|
| Risk Factors | 7 | 2023 | 5523 | 0.290 |
Why?
|
| Pharyngectomy | 3 | 2016 | 8 | 0.290 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2018 | 45 | 0.280 |
Why?
|
| Neoplasms, Experimental | 3 | 2005 | 269 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 868 | 0.270 |
Why?
|
| Oncogenes | 2 | 2020 | 97 | 0.270 |
Why?
|
| Goiter | 2 | 2018 | 43 | 0.270 |
Why?
|
| Radiotherapy Dosage | 4 | 2020 | 469 | 0.270 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 309 | 0.270 |
Why?
|
| Patient Selection | 3 | 2020 | 677 | 0.260 |
Why?
|
| Thyroid Gland | 3 | 2022 | 280 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 105 | 0.260 |
Why?
|
| Repressor Proteins | 3 | 2015 | 423 | 0.260 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 1172 | 0.260 |
Why?
|
| Brain Neoplasms | 4 | 2024 | 785 | 0.250 |
Why?
|
| Thyroid Nodule | 2 | 2016 | 59 | 0.250 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 21 | 0.240 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 1445 | 0.240 |
Why?
|
| ErbB Receptors | 2 | 2020 | 498 | 0.240 |
Why?
|
| Rhabdoid Tumor | 1 | 2024 | 20 | 0.240 |
Why?
|
| DNA Mutational Analysis | 5 | 2016 | 529 | 0.240 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 476 | 0.230 |
Why?
|
| Signal Transduction | 6 | 2024 | 3395 | 0.230 |
Why?
|
| Risk Assessment | 7 | 2018 | 2304 | 0.230 |
Why?
|
| Teratoma | 1 | 2024 | 52 | 0.230 |
Why?
|
| Databases, Factual | 3 | 2018 | 860 | 0.220 |
Why?
|
| Quinolones | 1 | 2024 | 56 | 0.220 |
Why?
|
| Hypothermia | 1 | 2003 | 26 | 0.220 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 2582 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 146 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1281 | 0.210 |
Why?
|
| Ganglioneuroblastoma | 1 | 2023 | 4 | 0.210 |
Why?
|
| Young Adult | 8 | 2022 | 6362 | 0.210 |
Why?
|
| DNA, Viral | 2 | 2022 | 262 | 0.210 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 42 | 0.210 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 18 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 247 | 0.210 |
Why?
|
| Head | 1 | 2003 | 137 | 0.210 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 449 | 0.210 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.210 |
Why?
|
| Oral Health | 2 | 2022 | 10 | 0.200 |
Why?
|
| Decision Making | 2 | 2020 | 669 | 0.200 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2023 | 113 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 341 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 250 | 0.200 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 185 | 0.200 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1064 | 0.190 |
Why?
|
| Lymphatic Metastasis | 5 | 2021 | 497 | 0.190 |
Why?
|
| Smoking | 3 | 2020 | 625 | 0.190 |
Why?
|
| Gastric Bypass | 1 | 2023 | 113 | 0.190 |
Why?
|
| Cloud Computing | 1 | 2021 | 13 | 0.190 |
Why?
|
| DNA Helicases | 2 | 2012 | 84 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2018 | 1496 | 0.190 |
Why?
|
| DNA Methylation | 3 | 2015 | 660 | 0.190 |
Why?
|
| Societies, Medical | 4 | 2018 | 581 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.190 |
Why?
|
| Transcriptome | 3 | 2021 | 654 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 374 | 0.190 |
Why?
|
| RNA, Messenger | 4 | 2016 | 2021 | 0.180 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 17 | 0.180 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2641 | 0.180 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 3658 | 0.180 |
Why?
|
| Parathyroidectomy | 2 | 2018 | 80 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 151 | 0.180 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 62 | 0.180 |
Why?
|
| Nuclear Proteins | 4 | 2012 | 726 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 585 | 0.180 |
Why?
|
| Larynx, Artificial | 2 | 2011 | 2 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 197 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2021 | 187 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 13 | 0.170 |
Why?
|
| Oncogene Protein v-akt | 1 | 2020 | 21 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 294 | 0.170 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 419 | 0.170 |
Why?
|
| Bacteria | 2 | 2023 | 481 | 0.170 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 238 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 146 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 217 | 0.170 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 28 | 0.170 |
Why?
|
| Cyclin D1 | 1 | 2020 | 84 | 0.170 |
Why?
|
| Checklist | 1 | 2020 | 61 | 0.170 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 44 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1727 | 0.170 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 64 | 0.170 |
Why?
|
| Genomics | 4 | 2024 | 774 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 192 | 0.170 |
Why?
|
| Brain Stem Neoplasms | 1 | 2019 | 17 | 0.170 |
Why?
|
| Health Resources | 1 | 2020 | 80 | 0.170 |
Why?
|
| Radiation Dosage | 1 | 2020 | 226 | 0.160 |
Why?
|
| Human papillomavirus 16 | 2 | 2016 | 38 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 189 | 0.160 |
Why?
|
| Neoplasms | 5 | 2023 | 3053 | 0.160 |
Why?
|
| Point Mutation | 1 | 2019 | 245 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 128 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 394 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 122 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2022 | 8209 | 0.160 |
Why?
|
| Glossectomy | 2 | 2016 | 4 | 0.160 |
Why?
|
| Consensus | 2 | 2018 | 362 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 188 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 366 | 0.150 |
Why?
|
| beta Catenin | 1 | 2020 | 266 | 0.150 |
Why?
|
| APOBEC Deaminases | 1 | 2017 | 5 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2018 | 98 | 0.150 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 384 | 0.150 |
Why?
|
| Computational Biology | 1 | 2021 | 549 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 268 | 0.150 |
Why?
|
| Reoperation | 3 | 2016 | 603 | 0.150 |
Why?
|
| Carboplatin | 3 | 2024 | 312 | 0.150 |
Why?
|
| Confidence Intervals | 1 | 2018 | 221 | 0.150 |
Why?
|
| Glottis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Metals | 1 | 2018 | 93 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 351 | 0.140 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 1705 | 0.140 |
Why?
|
| Hypocalcemia | 2 | 2014 | 44 | 0.140 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2364 | 0.140 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 110 | 0.140 |
Why?
|
| Animals | 16 | 2025 | 27476 | 0.140 |
Why?
|
| Survival Rate | 3 | 2020 | 1887 | 0.140 |
Why?
|
| Paclitaxel | 3 | 2024 | 475 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 175 | 0.140 |
Why?
|
| Adolescent | 7 | 2022 | 9299 | 0.140 |
Why?
|
| Arabinofuranosyluracil | 2 | 2007 | 6 | 0.140 |
Why?
|
| Sclerotherapy | 1 | 2016 | 16 | 0.140 |
Why?
|
| Thymidine Kinase | 2 | 2007 | 30 | 0.140 |
Why?
|
| Vascular Malformations | 1 | 2016 | 19 | 0.130 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2016 | 17 | 0.130 |
Why?
|
| Gene Silencing | 2 | 2014 | 178 | 0.130 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2016 | 11 | 0.130 |
Why?
|
| Exons | 3 | 2015 | 453 | 0.130 |
Why?
|
| Bleomycin | 1 | 2016 | 102 | 0.130 |
Why?
|
| Mice | 12 | 2025 | 11828 | 0.130 |
Why?
|
| Endoscopy | 2 | 2011 | 352 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2666 | 0.130 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2016 | 7 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2015 | 33 | 0.130 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 31 | 0.130 |
Why?
|
| Time Factors | 5 | 2018 | 5333 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 3 | 2009 | 511 | 0.130 |
Why?
|
| Receptor, Notch2 | 2 | 2012 | 6 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 588 | 0.130 |
Why?
|
| Proton Therapy | 1 | 2015 | 32 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1243 | 0.130 |
Why?
|
| Calcium | 2 | 2018 | 1178 | 0.130 |
Why?
|
| North America | 2 | 2013 | 184 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2018 | 344 | 0.130 |
Why?
|
| China | 2 | 2014 | 235 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 517 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2016 | 93 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 219 | 0.130 |
Why?
|
| Biopsy | 1 | 2019 | 1183 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 234 | 0.130 |
Why?
|
| Spores, Bacterial | 2 | 2005 | 18 | 0.120 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2015 | 48 | 0.120 |
Why?
|
| Carbolines | 1 | 2015 | 8 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 275 | 0.120 |
Why?
|
| Mandible | 1 | 2016 | 121 | 0.120 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 10 | 0.120 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 177 | 0.120 |
Why?
|
| Leukoplakia, Oral | 1 | 2014 | 12 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2018 | 352 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 168 | 0.120 |
Why?
|
| Algorithms | 4 | 2016 | 1896 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 68 | 0.120 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 15 | 0.120 |
Why?
|
| Gene Dosage | 2 | 2013 | 210 | 0.120 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Zenker Diverticulum | 1 | 2014 | 9 | 0.120 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 119 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2014 | 171 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 178 | 0.120 |
Why?
|
| Bacterial Toxins | 2 | 2005 | 114 | 0.110 |
Why?
|
| Age Distribution | 1 | 2014 | 199 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2020 | 688 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 311 | 0.110 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 11 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 961 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2016 | 213 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 280 | 0.110 |
Why?
|
| Metagenome | 1 | 2014 | 105 | 0.110 |
Why?
|
| Enteral Nutrition | 3 | 2020 | 105 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 38 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 806 | 0.110 |
Why?
|
| Ependymoma | 1 | 2013 | 18 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1125 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2023 | 1862 | 0.110 |
Why?
|
| Mutation, Missense | 2 | 2011 | 280 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 484 | 0.110 |
Why?
|
| Papanicolaou Test | 1 | 2013 | 39 | 0.110 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2012 | 49 | 0.110 |
Why?
|
| Receptor, Notch3 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Astrocytoma | 1 | 2013 | 82 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 397 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2025 | 1668 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2013 | 71 | 0.100 |
Why?
|
| Adoptive Transfer | 2 | 2021 | 169 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 353 | 0.100 |
Why?
|
| Vocal Cords | 2 | 2011 | 28 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 64 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 86 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 55 | 0.100 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 195 | 0.100 |
Why?
|
| Geography | 1 | 2012 | 227 | 0.100 |
Why?
|
| INDEL Mutation | 1 | 2011 | 32 | 0.100 |
Why?
|
| Oligodendroglioma | 1 | 2011 | 45 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 846 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 44 | 0.100 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2012 | 63 | 0.090 |
Why?
|
| Genes, p53 | 1 | 2011 | 109 | 0.090 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 74 | 0.090 |
Why?
|
| Child | 6 | 2022 | 7214 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2013 | 265 | 0.090 |
Why?
|
| Neurons | 3 | 2009 | 1588 | 0.090 |
Why?
|
| Models, Biological | 2 | 2015 | 1762 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 4 | 2005 | 1090 | 0.090 |
Why?
|
| Lipomatosis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 208 | 0.090 |
Why?
|
| Cisplatin | 2 | 2022 | 597 | 0.090 |
Why?
|
| Lipoma | 1 | 2010 | 27 | 0.080 |
Why?
|
| MPTP Poisoning | 1 | 2009 | 3 | 0.080 |
Why?
|
| Glioma | 1 | 2012 | 294 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 327 | 0.080 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 27 | 0.080 |
Why?
|
| DNA | 1 | 2015 | 1309 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 257 | 0.080 |
Why?
|
| Intestinal Neoplasms | 1 | 2010 | 67 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 693 | 0.080 |
Why?
|
| Safety Management | 2 | 2020 | 56 | 0.080 |
Why?
|
| Lung | 1 | 2015 | 1273 | 0.080 |
Why?
|
| Biomarkers | 2 | 2023 | 1768 | 0.080 |
Why?
|
| Speech, Alaryngeal | 1 | 2008 | 3 | 0.080 |
Why?
|
| Voice Quality | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 100 | 0.080 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 153 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2016 | 107 | 0.080 |
Why?
|
| Base Sequence | 1 | 2012 | 2329 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 984 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2024 | 1048 | 0.080 |
Why?
|
| Robotics | 1 | 2011 | 269 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2010 | 299 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2022 | 4309 | 0.080 |
Why?
|
| Microsurgery | 1 | 2008 | 90 | 0.070 |
Why?
|
| Oral Fistula | 1 | 2007 | 2 | 0.070 |
Why?
|
| Cutaneous Fistula | 1 | 2007 | 11 | 0.070 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2007 | 15 | 0.070 |
Why?
|
| Recurrence | 3 | 2018 | 1143 | 0.070 |
Why?
|
| Laryngoscopy | 2 | 2022 | 47 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 1084 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 2007 | 23 | 0.070 |
Why?
|
| Muscles | 1 | 2007 | 193 | 0.070 |
Why?
|
| Longevity | 2 | 2023 | 58 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 72 | 0.070 |
Why?
|
| Rabbits | 2 | 2005 | 639 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2008 | 148 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2005 | 274 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2023 | 3754 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 655 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 768 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2007 | 271 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 184 | 0.060 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2005 | 5 | 0.060 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 5 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2022 | 293 | 0.060 |
Why?
|
| Huntington Disease | 1 | 2005 | 39 | 0.060 |
Why?
|
| Bacteriolysis | 1 | 2004 | 1 | 0.060 |
Why?
|
| Behavior | 1 | 2005 | 85 | 0.060 |
Why?
|
| Length of Stay | 3 | 2014 | 743 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2005 | 35 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 134 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2004 | 81 | 0.060 |
Why?
|
| Glossitis, Benign Migratory | 1 | 2023 | 2 | 0.060 |
Why?
|
| Bacteria, Anaerobic | 1 | 2003 | 3 | 0.060 |
Why?
|
| Glossitis | 1 | 2023 | 3 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 100 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2015 | 313 | 0.060 |
Why?
|
| Tongue Diseases | 1 | 2023 | 10 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2024 | 307 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2024 | 126 | 0.060 |
Why?
|
| Histone Demethylases | 1 | 2023 | 32 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2003 | 27 | 0.060 |
Why?
|
| Microtubules | 1 | 2004 | 123 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 476 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1850 | 0.050 |
Why?
|
| Body Temperature | 1 | 2003 | 125 | 0.050 |
Why?
|
| Fluid Therapy | 1 | 2003 | 51 | 0.050 |
Why?
|
| Pharynx | 1 | 2023 | 44 | 0.050 |
Why?
|
| Adenoidectomy | 1 | 2023 | 23 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2003 | 83 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2003 | 116 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 374 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2003 | 207 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2003 | 121 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 432 | 0.050 |
Why?
|
| Clostridium Infections | 1 | 2004 | 125 | 0.050 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2022 | 11 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 60 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 979 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 919 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 95 | 0.050 |
Why?
|
| Parathyroid Glands | 1 | 2022 | 74 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 56 | 0.050 |
Why?
|
| Apoptosis | 2 | 2005 | 1717 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 354 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 263 | 0.050 |
Why?
|
| Lip | 1 | 2021 | 16 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 140 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 231 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 38 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 276 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 1214 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 550 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2020 | 27 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 145 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 1463 | 0.050 |
Why?
|
| Cell Line | 4 | 2005 | 2494 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 303 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 278 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 29 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 282 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 426 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 318 | 0.040 |
Why?
|
| Surgical Oncology | 1 | 2020 | 27 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 135 | 0.040 |
Why?
|
| Genes, myb | 1 | 2019 | 5 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 59 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 314 | 0.040 |
Why?
|
| India | 1 | 2020 | 125 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2003 | 774 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 67 | 0.040 |
Why?
|
| Deglutition | 1 | 2020 | 77 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1247 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 12 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 781 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1394 | 0.040 |
Why?
|
| Genes, myc | 1 | 2019 | 40 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1798 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 642 | 0.040 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2019 | 78 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 113 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 277 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 67 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 885 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 59 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 58 | 0.040 |
Why?
|
| Aging | 1 | 2023 | 721 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 259 | 0.040 |
Why?
|
| Lysine | 1 | 2019 | 150 | 0.040 |
Why?
|
| Hypoxia | 1 | 2003 | 654 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 269 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 82 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 103 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1227 | 0.040 |
Why?
|
| American Dental Association | 1 | 2017 | 9 | 0.040 |
Why?
|
| Evidence-Based Dentistry | 1 | 2017 | 10 | 0.040 |
Why?
|
| S-Nitrosoglutathione | 2 | 2009 | 10 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 326 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2009 | 22 | 0.040 |
Why?
|
| Mouth | 1 | 2017 | 48 | 0.040 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2009 | 56 | 0.040 |
Why?
|
| N-Methylaspartate | 2 | 2009 | 51 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2005 | 3237 | 0.040 |
Why?
|
| Indoles | 1 | 2019 | 300 | 0.040 |
Why?
|
| Electromyography | 1 | 2018 | 195 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 64 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 333 | 0.040 |
Why?
|
| Germ Cells | 1 | 2017 | 130 | 0.030 |
Why?
|
| Exanthema | 1 | 2016 | 40 | 0.030 |
Why?
|
| Cetuximab | 1 | 2016 | 115 | 0.030 |
Why?
|
| Neutropenia | 1 | 2016 | 214 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2016 | 18 | 0.030 |
Why?
|
| Amines | 1 | 2016 | 28 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2016 | 25 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 35 | 0.030 |
Why?
|
| Maryland | 1 | 2015 | 43 | 0.030 |
Why?
|
| Protein Transport | 2 | 2009 | 421 | 0.030 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2015 | 37 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 46 | 0.030 |
Why?
|
| Transfection | 2 | 2009 | 909 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 85 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 121 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 78 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 450 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2015 | 44 | 0.030 |
Why?
|
| Denmark | 1 | 2015 | 17 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 352 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 83 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 661 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2016 | 70 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1430 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 214 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 152 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 111 | 0.030 |
Why?
|
| Tadalafil | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2015 | 7 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 182 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 865 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 142 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2016 | 71 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2009 | 2384 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 373 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 183 | 0.030 |
Why?
|
| Analgesics | 1 | 2016 | 119 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 740 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 253 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 303 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 33 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 899 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 52 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 200 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1671 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 283 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 95 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 180 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2013 | 83 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 201 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 158 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3465 | 0.030 |
Why?
|
| Protein Binding | 2 | 2009 | 1491 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2763 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 432 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2015 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2005 | 816 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 849 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 294 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2012 | 10 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2009 | 2012 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2884 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 606 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 40 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 21 | 0.020 |
Why?
|
| Seroma | 1 | 2011 | 7 | 0.020 |
Why?
|
| Learning Curve | 1 | 2011 | 19 | 0.020 |
Why?
|
| Vocal Cord Paralysis | 1 | 2011 | 27 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 119 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 711 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 59 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 86 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 94 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 100 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 2063 | 0.020 |
Why?
|
| Hematoma | 1 | 2011 | 108 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 301 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 791 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 791 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 3024 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 298 | 0.020 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2009 | 45 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 146 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 331 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 223 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 309 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1221 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2007 | 59 | 0.020 |
Why?
|
| Visual Fields | 1 | 2008 | 98 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 953 | 0.020 |
Why?
|
| Magnetics | 1 | 2007 | 41 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 557 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 40 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 124 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 571 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 352 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2008 | 199 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 3174 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 245 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 678 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 353 | 0.020 |
Why?
|
| Densitometry | 1 | 2005 | 29 | 0.020 |
Why?
|
| Escape Reaction | 1 | 2005 | 12 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2005 | 13 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 689 | 0.020 |
Why?
|
| Electron Transport | 1 | 2005 | 74 | 0.020 |
Why?
|
| Retinal Degeneration | 1 | 2005 | 29 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 238 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 88 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 258 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 126 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 81 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 274 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 291 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2005 | 96 | 0.010 |
Why?
|
| Cysteine | 1 | 2005 | 137 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 222 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 285 | 0.010 |
Why?
|
| Spores | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cesium Radioisotopes | 1 | 2003 | 12 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 341 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 294 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2005 | 279 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 276 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 198 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 210 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2004 | 212 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 511 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 397 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 601 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 983 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2004 | 188 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 368 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 378 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2005 | 606 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 578 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 554 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1576 | 0.010 |
Why?
|
| Drosophila | 1 | 2005 | 522 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 1158 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2294 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 4041 | 0.010 |
Why?
|